Search Results

There are 10984 results for: content related to: Association between nonnaproxen NSAIDs, COX-2 inhibitors and hospitalization for acute myocardial infarction among the elderly: a retrospective cohort study

  1. The effect of rofecoxib on the pharmacodynamics and pharmacokinetics of warfarin

    Clinical Pharmacology & Therapeutics

    Volume 68, Issue 6, December 2000, Pages: 626–636, Jules I. Schwartz, Kathleen J. Bugianesi, David L. Ebel, Marina De Smet, Rita Haesen, Patrick J. Larson, Amy Ko, Rene Verbesselt, Thomas L. Hunt, Robert Lins, Simone Lens, Arturo G. Porras, John Dieck, Bart Keymeulen and Barry J. Gertz

    Article first published online : 12 DEC 2000, DOI: 10.1067/mcp.2000.112244

  2. Enhancement of dissolution rate of rofecoxib using solid dispersions with urea

    Drug Development Research

    Volume 63, Issue 4, December 2004, Pages: 181–189, Chengsheng Liu, Kashappa Goud H. Desai, Chenguang Liu and Hyun J. Park

    Article first published online : 28 MAR 2005, DOI: 10.1002/ddr.10412

  3. You have free access to this content
    Arthritis & Rheumatism, 2001 Annual Scientific Meeting Abstracts, November 10–15, 2001, San Francisco, CA

    Arthritis & Rheumatism

    Volume 44, Issue S9, September 2001, Pages: 277–390,

    Article first published online : 22 FEB 2002, DOI: 10.1002/1529-0131(200109)44:9+<::AID-ART427>3.0.CO;2-4

  4. NSAIDs – COX-2 Inhibitors – Risks and Benefits

    Pharmacovigilance, Second Edition

    K. Arnold Chan, S. Christopher Jones, Pages: 583–602, 2007

    Published Online : 7 FEB 2007, DOI: 10.1002/9780470059210.ch47

  5. Lack of Pharmacokinetic Interaction between Rofecoxib and Methotrexate in Rheumatoid Arthritis Patients

    The Journal of Clinical Pharmacology

    Volume 41, Issue 10, October 2001, Pages: 1120–1130, Dr. Jules I. Schwartz, Dr. Nancy G. B. Agrawal, Dr. Peggy H. Wong, Dr. Kenneth A. Bachmann, Dr. Arturo G. Porras, Ms. Jutta L. Miller, Mr. David L. Ebel, Dr. Marshall R. Sack, Dr. Gregory B. Holmes, Dr. Jan S. Redfern and Dr. Barry J. Gertz

    Article first published online : 8 MAR 2013, DOI: 10.1177/00912700122012616

  6. Characterization of rofecoxib as a cyclooxygenase-2 isoform inhibitor and demonstration of analgesia in the dental pain model

    Clinical Pharmacology & Therapeutics

    Volume 65, Issue 3, March 1999, Pages: 336–347, Elliot W. Ehrich, Aimee Dallob, Inge De Lepeleire, Anne Van Hecken, Denis Riendeau, Weiying Yuan, Arturo Porras, Johanna Wittreich, James R. Seibold, Paul De Schepper, Donald R. Mehlisch and Barry J. Gertz

    Article first published online : 10 MAR 1999, DOI: 10.1016/S0009-9236(99)70113-X

  7. NSAID switching and short-term gastrointestinal outcome rates after the withdrawal of rofecoxib

    Pharmacoepidemiology and Drug Safety

    Volume 18, Issue 12, December 2009, Pages: 1134–1142, Sebastian Schneeweiss, Robert J. Glynn, Jerry Avorn, Muhammad Mamdani, Helen Mogun and Daniel H. Solomon

    Article first published online : 20 OCT 2009, DOI: 10.1002/pds.1826

  8. An Evaluation of the Dose-Dependent Inhibition of CYP1A2 by Rofecoxib Using Theophylline as a CYP1A2 Probe

    The Journal of Clinical Pharmacology

    Volume 43, Issue 10, October 2003, Pages: 1082–1090, Dr. Kenneth Bachmann, Dr. Donald White, Dr. Luis Jauregui, Dr. Jules I. Schwartz, Dr. Nancy G. B. Agrawal, Mr. Ralph Mazenko, Mr. Patrick J. Larson and Dr. Arturo G. Porras

    Article first published online : 8 MAR 2013, DOI: 10.1177/0091270003257454

  9. Cardiovascular Risks of Cyclooxygenase Inhibition

    Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

    Volume 26, Issue 7, July 2006, Pages: 919–938, Dr. Zachary A. Stacy, Dr. Paul P. Dobesh and Dr. Toby C. Trujillo

    Article first published online : 6 JAN 2012, DOI: 10.1592/phco.26.7.919

  10. The trade-off between cardiovascular and gastrointestinal effects of rofecoxib

    Pharmacoepidemiology and Drug Safety

    Volume 14, Issue 7, July 2005, Pages: 437–441, Stefan R. Florentinus, Eibert R. Heerdink, Antonius de Boer, Liset van Dijk and Hubert G. M. Leufkens

    Article first published online : 2 JUN 2005, DOI: 10.1002/pds.1123

  11. High frequency of use of rofecoxib at greater than recommended doses: cause for concern

    Pharmacoepidemiology and Drug Safety

    Volume 13, Issue 6, June 2004, Pages: 339–343, Marie R. Griffin, C. Michael Stein, David J. Graham, James R. Daugherty, Patrick G. Arbogast and Wayne A. Ray

    Article first published online : 15 JUL 2003, DOI: 10.1002/pds.879

  12. A New Cyclooxygenase-2 Inhibitor, Rofecoxib (VIOXX®), Did Not Alter the Antiplatelet Effects of Low-Dose Aspirin in Healthy Volunteers

    The Journal of Clinical Pharmacology

    Volume 40, Issue 12, December 2000, Pages: 1509–1515, Dr. Howard E. Greenberg, Dr. Keith Gottesdiener, Ms. Martha Huntington, Ms. Peggy Wong, Ms. Pat Larson, Ms. Lynn Wildonger, Ms. Lisa Gillen, Ms. Ellen Dorval and Dr. Scott A. Waldman

    Article first published online : 19 MAR 2013, DOI: 10.1177/009127000004001224

  13. You have free access to this content
    Rofecoxib, a specific inhibitor of cyclooxygenase 2, with clinical efficacy comparable with that of diclofenac sodium: Results of a one-year, randomized, clinical trial in patients with osteoarthritis of the knee and hip

    Arthritis & Rheumatism

    Volume 43, Issue 5, May 2000, Pages: 978–987, Grant W. Cannon, Jacques R. Caldwell, Peter Holt, Barry McLean, Beth Seidenberg, James Bolognese, Elliot Ehrich, Suarabh Mukhopadhyay and Brian Daniels

    Article first published online : 2 APR 2001, DOI: 10.1002/1529-0131(200005)43:5<978::AID-ANR4>3.0.CO;2-0

  14. Effect of Rofecoxib on Prednisolone and Prednisone Pharmacokinetics in Healthy Subjects

    The Journal of Clinical Pharmacology

    Volume 43, Issue 2, February 2003, Pages: 187–192, Jules I. Schwartz, Saurabh Mukhopadhyay, Arturo G. Porras, Kala-Jyoti Viswanathan-Aiyer, Sherilyn Adcock, David L. Ebel and Barry J. Gertz

    Article first published online : 8 MAR 2013, DOI: 10.1177/0091270002239828

  15. Cardiovascular risk of selective cyclooxygenase-2 inhibitors and other non-aspirin non-steroidal anti-inflammatory medications

    Pharmacoepidemiology and Drug Safety

    Volume 15, Issue 9, September 2006, Pages: 641–652, Priscilla Velentgas, William West, Carolyn C. Cannuscio, Douglas J. Watson and Alexander M. Walker

    Article first published online : 4 JAN 2006, DOI: 10.1002/pds.1192

  16. Effect of Rofecoxib on the Pharmacokinetics of Chronically Administered Oral Contraceptives in Healthy Female Volunteers

    The Journal of Clinical Pharmacology

    Volume 42, Issue 2, February 2002, Pages: 215–221, Dr. Jules I. Schwartz, Peggy H. Wong, Dr. Arturo G. Porras, Mr. David L. Ebel, Dr. Thomas R. Hunt and Dr. Barry J. Gertz

    Article first published online : 8 MAR 2013, DOI: 10.1177/00912700222011139

  17. Comparative Inhibitory Activity of Rofecoxib, Meloxicam, Diclofenac, Ibuprofen, and Naproxen on COX-2 versus COX-1 in Healthy Volunteers

    The Journal of Clinical Pharmacology

    Volume 40, Issue 10, October 2000, Pages: 1109–1120, Dr. Anne van Hecken, Dr. Jules I. Schwartz, Dr. Marleen Depré, Dr. Inge de Lepeleire, Ms. Aimee Dallob, Dr. Wesley Tanaka, Ms. Kathleen Wynants, Dr. Agnes Buntinx, Dr. Jef Arnout, Ms. Peggy H. Wong, Mr. David L. Ebel, Dr. Barry J. Gertz and Dr. Paul J. de Schepper

    Article first published online : 8 MAR 2013, DOI: 10.1177/009127000004001005

  18. You have free access to this content
    Antagonism of the antithrombotic and anti-atherosclerotic actions of aspirin by rofecoxib in the cholesterol-fed rabbit

    British Journal of Pharmacology

    Volume 164, Issue 2b, September 2011, Pages: 561–569, G Kaber, B Kaiser, D Baumgärtel-Allekotte, BH Rauch, S Noßmann, KH Heim, AA Weber, N Nagy, JW Fischer and K Schrör

    Article first published online : 28 AUG 2011, DOI: 10.1111/j.1476-5381.2011.01392.x

  19. Abstracts of the 21st International Conference on Pharmacepidemiology & Therapeutic Risk Management

    Pharmacoepidemiology and Drug Safety

    Volume 14, Issue S2, September 2005, Pages: S1–S218,

    Article first published online : 15 AUG 2005, DOI: 10.1002/pds.1136

  20. Cyclooxygenase-2 inhibition by rofecoxib reverses naturally occurring fever in humans

    Clinical Pharmacology & Therapeutics

    Volume 65, Issue 6, June 1999, Pages: 653–660, Jules I. Schwartz, Chi-Chung Chan, Saurabh Mukhopadhyay, Kathleen J. McBride, Terry M. Jones, Sherilyn Adcock, Carl Moritz, Jerris Hedges, Kenneth Grasing, David Dobratz, Robert A. Cohen, Michael H. Davidson, Kenneth A. Bachmann and Barry J. Gertz

    Article first published online : 17 JUN 1999, DOI: 10.1016/S0009-9236(99)90087-5